Who is the manufacturer of MYLABONE ULTRASOUND SYSTEM?

Esaote Europe B.V. filed the 510(k) submission for MYLABONE ULTRASOUND SYSTEM (K101605).

What is the FDA product code for MYLABONE ULTRASOUND SYSTEM?

IYN. It is classified under 21 CFR 892.1550 as a Class 2 device in the Radiology panel.

What is the regulatory pathway for MYLABONE ULTRASOUND SYSTEM?

510(k) clearance (submission type: Traditional).

What are the predicate devices for MYLABONE ULTRASOUND SYSTEM?

MyLabFive (K083882); NanoMaxx (K092058).

Who can help prepare an FDA 510(k) submission like MYLABONE ULTRASOUND SYSTEM?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

MYLABONE ULTRASOUND SYSTEM

K101605 · Esaote Europe B.V. · IYN · Aug 31, 2010 · Radiology

Device Facts

Record ID	K101605
Device Name	MYLABONE ULTRASOUND SYSTEM
Applicant	Esaote Europe B.V.
Product Code	IYN · Radiology
Decision Date	Aug 31, 2010
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 892.1550
Device Class	Class 2
Attributes	Pediatric, 3rd-Party Reviewed

Intended Use

Esaote's MyLabOne is an arm-held ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small Organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Obstetrics/Gynaecology, Transvaginal, Transrectal, Pediatric, Intraoperative Abdominal, and Other: Urology. The system provides imaging for guidance of biopsy and imaging to assist in t the placement of needles and catheters in vascular or other anatomical structures as well as peripheral nerve blocks in Musculoskeletal applications.

Device Story

MyLabOne is a battery-operated, portable, arm-held ultrasound system. It processes acoustic signals from phased, convex, and linear array probes to generate diagnostic images. Imaging modes include B-Mode, M-Mode, Amplitude Doppler, Tissue Enhancement Imaging (TEI), Color Flow Mapping, and Pulse Wave Doppler. The device features an LCD touchscreen for user interaction, data entry, and annotation. It includes internal storage and supports external archiving via LAN/USB. Used in clinical settings by healthcare professionals for diagnostic studies and procedural guidance (biopsy, needle/catheter placement, nerve blocks). Output is displayed on the integrated screen to assist clinical decision-making. Benefits include portability and real-time visualization for minimally invasive procedures.

Clinical Evidence

Bench testing only. Verification and validation conducted per 21 CFR 820.30. Compliance with IEC 60601-1, IEC 60601-1-2, IEC 60601-2-37, ISO 10993-1, and AIUM/NEMA UD-2/UD-3 standards for acoustic output and thermal/mechanical indices.

Technological Characteristics

Portable, battery-powered ultrasound system with LCD touchscreen. Supports phased, convex, and linear array probes. Imaging modes: B, M, PWD, Color Doppler, Amplitude Doppler, TEI, and XView. Connectivity: LAN/USB for data storage. Safety standards: IEC 60601-1, IEC 60601-2-37. Biocompatibility: ISO 10993-1.

Indications for Use

Indicated for diagnostic ultrasound imaging in patients requiring Cardiac, Peripheral Vascular, Neonatal/Adult Cephalic, Small Organ (breast, thyroid, testicles), Musculoskeletal, Abdominal, Fetal, OB/GYN, Transvaginal, Transrectal, Pediatric, Intraoperative Abdominal, and Urological exams. Includes needle/catheter placement guidance and peripheral nerve blocks.

Regulatory Classification

Identification

An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.

Predicate Devices

MyLabFive (K083882)
NanoMaxx (K092058)

Related Devices

K191072 — 7410 Ultrasound System (MyLabSigma) · Esaote, S.p.A. · Jun 10, 2019
K083882 — MYLABFIVE · Esaote Europe B.V. · Jan 30, 2009
K170870 — Site~Rite Halcyon Diagnostic Ultrasound System · Chison Medical Imaging Co., Ltd. · Jul 6, 2017
K142077 — MYLABGAMMA · Esaote, S.p.A. · Sep 12, 2014
K193510 — Terason uSmart3200T Ultrasound System · Teratech Corporation · Jan 28, 2020

Submission Summary (Full Text)

{0}------------------------------------------------ - K101605 AUG 31 2010 510(k) Summary The following 510(k) summary has been prepared pursuant to requirements specified in 21CFR 1807.92(a). 807.92(a)(1) # Submitter Information Esaote Europe B.V. Philipsweg 1 Maastricht 6227AJ The Netherlands Contact Person: ### Allison Scott, RAC 317.569.9500 x106 ascott@ansongroup.com Date: March 22, 2010 807.92(a)(2) Trade Name: MyLabOne Ultrasound System Common Name: Ultrasound Imaging System Classification Name | e(s): | Ultrasonic pulse Doppler imaging system | 892.1550 | |-------|-----------------------------------------|----------| | | Ultrasonic pulsed echo imaging system | 892.1560 | | | Diagnostic ultrasonic transducer | 892.1570 | Classification Number: 90IYN, 90IYO, 90ITX l {1}------------------------------------------------ ### 807.92(a)(3) # Predicate Device(s) | K083882 | MyLabFive | Esaote Europe B.V. | |---------|-----------|--------------------| | K092058 | NanoMaxx | SonoSite, Inc. | Additional substantial equivalence information is provided in the following substantial equivalence comparison table. 807.92 (a)(4) # Device Description The MyLabOne is a battery operated, portable ultrasound system used to perform diagnostic general ultrasound studies. Its primary modes of operation are: B-Mode, M-Mode, Amplitude Doppler (AD), Tissue Enhancement Imaging (TEI), Color Flow Mapping (CFM) and Pulse Wave Doppler. The MyLabOne is equipped with a LCD Color Display. The LCD Display includes touch screen technology for a simple and intuitive activation of functions and data entry for patient information and screen annotations. The MyLabOne can drive phased (PA), convex (CA) and linear array (LA) probes. The MyLabOne is equipped with an internal Hard Disk and with an optional external DVD-RW disk drive that can be used for image storage. Data can also be stored directly to external archiving media (hard-disk, PC, server) via a LAN/USB port. Optional accessory devices available for the MyLabOne include a monochrome or color page printer, a desk stand (for use on a desk or cart) and a mobile trolley equipped with four swiveling wheels and peripheral holder. {2}------------------------------------------------ #### 807.92(a)(5) ### Intended Use(s) Esaote's MyLabOne is an arm-held ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small Organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Obstetrics/Gynaecology, Transvaginal, Transrectal, Pediatric, Intraoperative Abdominal, and Other: Urology. The system provides imaging for guidance of biopsy and imaging to assist in t the placement of needles and catheters in vascular or other anatomical structures as well as peripheral nerve blocks in Musculoskeletal applications. 807.92(a)(6) ### Technological Characteristics Esaote believes that the MyLabOne is substantial equivalent to Esaote's MyLabFive product (K083882) and SonoSite's Nanomaxx product (K092058). - · Clinical uses for which the MyLabOne is designed are equivalent to those cleared for the Esaote MyLabFive and the SonoSite NanoMaxx. - · The MyLabOne, the Esaote MyLabFive and the SonoSite NanoMaxx are designed to meet the IEC60601-1 and the IEC60601-2-37 safety requirements. - · The MyLabOne, the Esaote MyLabFive and the SonoSite NanoMaxx provide an Acoustic Output Display feature per AIUM / NEMA standards, with equivalent Ispta and MI maximal values. - · The MyLabOne, the Esaote MyLabFive and the SonoSite NanoMaxx provide a similar measurements and analysis package, with equal accuracy and precision. - · The MyLabOne, the Esaote MyLabFive and the SonoSite NanoMaxx have digital storage capabilities, including Network connectivity. - · The MyLabOne, the Esaote MyLabFive and the SonoSite NanoMaxx are designed to be powered by battery when no main power is available. - · The MyLabOne image modes are available on other FDA cleared ultrasound systems. for instance the Esaote MyLabFive and Sonosite NanoMaxx. 3 {3}------------------------------------------------ 807.92(b)(1) # Non-Clinical Testing Verification and validation tests have been conducted in accordance with design controls per CFR 820.30. The system has been designed to meet the following standards: - . IEC 60601-I - IEC 60601-1-2 . - IEC 60601-2-37 . - ISO 10993-1 . - AIUM/NEMA UD-3 Standard for Real Time Display of Thermal and Mechanical . Acoustic Output Indices on Diagnostic Ultrasound Equipment - AIUM/NEMA UD-2 Acoustic Output Measurement Standard for Diagnostic . Ultrasound . . .. .. . . {4}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/4/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract image of an eagle. Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Esaote Europe B.V. % Mr. Mark Job Responsible Third Party Official Regulatory Technology Services 1394 25th Street NW BUFFALO MN 55313 2010 3 1 Re: K101605 Trade/Device Name: MyLabOne Regulation Number: 21 CFR 892.1550 Regulation Name: Ultrasonic pulsed doppler imaging system Regulatory Class: II Product Code: IYN, IYO, and ITX Dated: August 18, 2010 Received: August 19, 2010 Dear Mr. Job: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. This determination of substantial equivalence applies to the following transducers intended for use with the MyLabOne, as described in your premarket notification: ### Transducer Model Number {5}------------------------------------------------ If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. If you have any questions regarding the content of this letter, please contact Shahram Vaezy at (301) 796-6242. Sincerely yours. signature Jonald St. Pierre Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure(s) {6}------------------------------------------------ 510(k) Number (if known): |<{ 0(lof(005 Device Name: MyLabOne Indications for Use: Esaote's MyLabOne is an arm-held ultrasound system used to perform diagnostic general ultrasound studies including Cardiac, Peripheral Vascular, Neonatal Cephalic, Adult Cephalic, Small Organ, Musculoskeletal (Conventional and Superficial), Abdominal, Fetal, Obstetrics/Gynaecology, Transvaginal, Transrectal, Pediatric, Intraoperative Abdominal and Other: Urology. The system provides imaging for guidance of biopsy and imaging to assist in the placement of needles and catheters in vascular or other anatomical structures as well as peripheral nerve blocks in Musculoskeletal applications. Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) D.m.d. JHL Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K101605 MyLabOne Response to FDA Deficiencies {7}------------------------------------------------ ### MyLabOne | | | Mode of Operations | | | | | | | | | |-------------------------------------------------------------|---|--------------------|-----|-----|------------------|----------------------|-----------------|-----|----------------------------------------|-----------------| | Clinical Application | B | M | PWD | CWD | Color Doppler | Amplitude Doppler | Combined [3] | TVM | Tissue Enhancement Imaging (TEI) | Other (specify) | | Ophthalmic | | | | | | | | | | | | Fetal/Obstetrics/Oyn | N | N | N | N | N | N | N | | N | 4 | | Abdominal | N | N | N | N | N | N | N | | N | 4 | | Intraoperative (Abdominal) | N | N | N | N | N | N | N | | N | 4 | | Intraoperative Neurological | | | | | | | | | | | | Pediatric | N | N | N | N | N | N | N | | N | 4 | | Small Organ [1] | N | N | N | N | N | N | N | | N | 4 | | Neonatal Cephalic | N | N | N | N | N | N | N | | N | 4 | | Adult Cephalic | N | N | N | N | N | N | N | | N | 4 | | Cardiac [2] | N | N | N | N | N | N | N | | N | 4 | | Transesophageal (Cardiac) | | | | | | | | | | | | Transesophageal (Non Cardiac) | | | | | | | | | | | | Transrectal | N | N | N | N | N | N | N | | N | 4 | | Transvaginal | N | N | N | N | N | N | N | | N | 4 | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular (including vascular access) | N | N | N | N | N | N | N | | N | 4 | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal Conventional (including Nerve Blocking) | N | N | N | N | N | N | N | | N | 4 | | Musculo-skeletal Superficial (including Nerve Blocking) | N | N | N | N | N | N | N | | N | 4 | | Other (Urological) | N | N | N | N | N | N | N | | N | 4 | N=new indication; P=previously cleared by FDA; E= added under Appendix E Additional Comments: - (1) Small Organs includes Breast, Thyroid and Testicles (2) Cardiac is Adult and Pediatric - [3] Combined modes are: B + M + PW + CFM + PD - XVicw િનો Prescription Use Only (Per 21 CFR 801 Part D) Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD) (Division Sign-Off) Division of Radiological Devices Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety 510K. K101605 {8}------------------------------------------------ ### SL3323 | Clinical Application | B | M | PWD | CWD | Color Doppler | Amplitude Doppler | Combined [3] | TVM | Tissue Enhancement Imaging (TEI) | Other (specify) | |-------------------------------------------------------------|---|---|-----|-----|------------------|----------------------|-----------------|-----|----------------------------------------|-----------------| | Ophthalmic | | | | | | | | | | | | Fetal/Obstetrics/Gyn | | | | | | | | | | | | Abdominal | N | N | N | | N | N | N | | N | 4 | | Intraoperative (Abdominal) | N | N | N | | N | N | N | | N | 4 | | Intraoperative Neurological | | | | | | | | | | | | Pediatric | N | N | N | | N | N | N | | N | 4 | | Small Organ [1] | N | N | N | | N | N | N | | N | 4 | | Neonatal Cephalic | N | N | N | | N | N | N | | N | 4 | | Adult Cephalic | | | | | | | | | | | | Cardiac [2] | | | | | | | | | | | | Transesophageal (Cardiac) | | | | | | | | | | | | Transesophageal (Non Cardiac) | | | | | | | | | | | | Transrectal | | | | | | | | | | | | Transvaginal | | | | | | | | | | | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular (including vascular access) | N | N | N | | N | N | N | | N | 4 | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal Conventional (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Musculo-skeletal Superficial (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Other (Urological) | | | | | | | | | | | The SL3323 probe is to be cleared via this submssion N=new indication; P=previously cleared by FDA; E= added under Appendix E Additional Comments: - (1) Small Organs includes Breast, Thyroid and Testicles [기 Cardiac is Adult and Pediatric [3] Combined modes are: B + M + PW + CFM + PD (4) XView Prescription Use Only (Per 21 CFR 801 Part D) Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD) ﯿ . (Division Sign-Off) (Division of Radiological Devices Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Collice of In Vitro Diagnostic Device Evaluation and Safety K101605 510K. {9}------------------------------------------------ ### SL3116 | | Mode of Operations | | | | | | | | | | |-------------------------------------------------------------|--------------------|---|-----|-----|------------------|----------------------|-----------------|-----|----------------------------------------|-----------------| | Clinical Application | B | M | PWD | CWD | Color Doppler | Amplitude Doppler | Combined [3] | TVM | Tissue Enhancement Imaging (TEI) | Other (specify) | | Ophthalmic | | | | | | | | | | | | Fetal / Obstetrics / Gyn | | | | | | | | | | | | Abdominal | | | | | | | | | | | | Intraoperative (Abdominal) | N | N | N | | N | N | N | | N | 4 | | Intraoperative Neurological | | | | | | | | | | | | Pediatric | N | N | N | | N | N | N | | N | 4 | | Small Organ [1] | N | N | N | | N | N | N | | N | 4 | | Neonatal Cephalic | | | | | | | | | | | | Adult Cephalic | | | | | | | | | | | | Cardiac [2] | | | | | | | | | | | | Transesophageal (Cardiac) | | | | | | | | | | | | Transesophageal (Non Cardiac) | | | | | | | | | | | | Transrectal | | | | | | | | | | | | Transvaginal | | | | | | | | | | | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular (including vascular access) | N | N | N | | N | N | N | | N | 4 | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal Conventional (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Musculo-skeletal Superficial (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Other (Urological) | | | | | | | | | | | The SL3116 probe is to be cleared via this submssion N=new indication; P=previously cleared by FDA; E= added under Appendix E Additional Comments: - [1] [2] (3) [4] Small Organs includes Breast, Thyroid and Testicles Cardiac is Adult and Pediatric Combined modes are: B + M + PW + CFM + PD XView > Prescription Use Only (Per 21 CFR 801 Part D) Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD) (Division Sign-Off) Division of Radiological De Office of In ce Evaluation and Safety 510K K101605 {10}------------------------------------------------ ### SC3121 | | Mode of Operations | | | | | | | | | | |-------------------------------------------------------------|--------------------|---|-----|-----|------------------|----------------------|--------------|-----|----------------------------------------|-----------------| | Clinical Application | B | M | PWD | CWD | Color Doppler | Amplitude Doppler | Combined [3] | TVM | Tissue Enhancement Imaging (TEI) | Other (specify) | | Ophthalmic | | | | | | | | | | | | Fetal/Obstetrics/Gyn | N | N | N | | N | N | N | | N | 4 | | Abdominal | N | N | N | | N | N | N | | N | 4 | | Intraoperative (Abdominal) | | | | | | | | | | | | Intraoperative Neurological | | | | | | | | | | | | Pediatric | N | N | N | | N | N | N | | N | 4 | | Small Organ [1] | | | | | | | | | | | | Neonatal Cephalic | N | N | N | | N | N | N | | N | 4 | | Adult Cephalic | | | | | | | | | | | | Cardiac [2] | N | N | N | | N | N | N | | N | 4 | | Transesophageal (Cardiac) | | | | | | | | | | | | Transesophageal (Non Cardiac) | | | | | | | | | | | | Transrectal | | | | | | | | | | | | Transvaginal | | | | | | | | | | | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular (including vascular access) | N | N | N | | N | N | N | | N | 4 | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal Conventional (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Musculo-skeletal Superficial (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Other (Urological) | N | N | N | | N | N | N | | N | 4 | The SC3121 probe is to be cleared via this submssion Nenew indication; P=previously cleared by FDA; E= added under Appendix E Additional Comments: - (1) Small Organs includes Breast, Thyroid and Testicles (기 Cardiac is Adult and Pediatric (ર) Combined modes are: B + M + PW + CFM + PD XView - |4) Prescription Use Only (Per 21 CFR 801 Part D) Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD) (Division Sign-Off) Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety 510K.K101665 {11}------------------------------------------------ ### SC3123 | | Mode of Operations | | | | | | | | | | |-------------------------------------------------------------|--------------------|---|-----|-----|------------------|----------------------|-----------------|-----|----------------------------------------|-----------------| | Clinical Application | B | M | PWD | CWD | Color Doppler | Amplitude Doppler | Combined [3] | TVM | Tissue Enhancement Imaging (TEI) | Other (specify) | | Ophthalmic | | | | | | | | | | | | Fetal/Obstetrics/Gyn | | | | | | | | | | | | Abdominal | | | | | | | | | | | | Intraoperative (Abdominal) | | | | | | | | | | | | Intraoperative Neurological | | | | | | | | | | | | Pediatric | N | N | N | N | N | N | N | | N | 4 | | Small Organ [1] | N | N | N | N | N | N | N | | N | 4 | | Neonatal Cephalic | N | N | N | N | N | N | N | | N | 4 | | Adult Cephalic | | | | | | | | | | | | Cardiac [2] | N | N | N | N | N | N | N | | N | 4 | | Transesophageal (Cardiac) | | | | | | | | | | | | Transesophageal (Non Cardiac) | | | | | | | | | | | | Transrectal | | | | | | | | | | | | Transvaginal | | | | | | | | | | | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular (including vascular access) | N | N | N | N | N | N | N | | N | 4 | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal Conventional (including Nerve Blocking) | N | N | N | N | N | N | N | | N | 4 | | Musculo-skeletal Superficial (including Nerve Blocking) | N | N | N | N | N | N | N | | N | 4 | | Other (Urological) | | | | | | | | | | | The SC3123 probe is to be cleared via this submssion [1] [기 (3) (ব) N=new indication; P=previously cleared by FDA; E= added under Appendix E Additional Comments: - Small Organs includes Breast, Thyroid and Testicles Cardiac is Adult and Pediatric Combined modes are: B + M + PW + CFM + PD XView Prescription Use Only (Per 21 CFR 801 Part D) Concurrence of CDRH. Office of In Vitro Diagnostics Devices (OIVD) S.D.R. (Division Sign-Off) Division of Radiological Devices Office of in Vitro Diagnostic Devices Office of in Vitro Diagnostic Device Evaluation and Safety 510K Ki6605 {12}------------------------------------------------ #### SC3421 | | | Mode of Operations | | | | | | | | | |-------------------------------------------------------------|---|--------------------|-----|-----|------------------|----------------------|-----------------|-----|----------------------------------------|-----------------| | Clinical Application | B | M | PWD | CWD | Color Doppler | Amplitude Doppler | Combined [3] | TVM | Tissue Enhancement Imaging (TEI) | Other (specify) | | Ophthalmic | | | | | | | | | | | | Fetal/Obstetrics/Gyn | N | N | N | | N | N | N | | N | 4 | | Abdominal | N | N | N | | N | N | N | | N | 4 | | Intraoperative (Abdominal) | | | | | | | | | | | | Intraoperative Neurological | | | | | | | | | | | | Pediatric | N | N | N | | N | N | N | | N | 4 | | Small Organ [1] | | | | | | | | | | | | Neonatal Cephalic | | | | | | | | | | | | Adult Cephalic | | | | | | | | | | | | Cardiac [2] | | | | | | | | | | | | Transesophageal (Cardiac) | | | | | | | | | | | | Transesophageal (Non Cardiac) | | | | | | | | | | | | Transrectal | | | | | | | | | | | | Transvaginal | | | | | | | | | | | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular (including vascular access) | N | N | N | | N | N | N | | N | 4 | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal Conventional (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Musculo-skeletal Superficial (including Nerve Blocking) | N | N | N | | N | N | N | | N | 4 | | Other (Urological) | N | N | N | | N | N | N | | N | 4 | The SC3421 probe is to be cleared via this submasion N=new indication; P=previously cleared by FDA; E= added under Appendix E Additional Comments: . - (1) Small Organs includes Breast, Thyroid and Testicles Cardiac is Adult and Pediatric (2) (3) Combined modes are: B + M + PW + CFM + PD (4) XVicw Prescription Use Only (Per 21 CFR 801 Part D) Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD) (Drision Sign-Off) (Simsion of Radiological Devices Office of the Diagnostic Devices Office of In Vitro Diagnostic Device Evaluation and Safety 510K K16605 {13}------------------------------------------------ #### SE3123 | | Mode of Operations | | | | | | | | | | |-------------------------------------------------------------|--------------------|---|-----|-----|------------------|----------------------|-----------------|-----|----------------------------------------|-----------------| | Clinical Application | B | M | PWD | CWD | Color Doppler | Amplitude Doppler | Combined [3] | TVM | Tissue Enhancement Imaging (TEI) | Other (specify) | | Ophthalmic | | | | | | | | | | | | Fetal/Obstetrics/Gyn | N | N | N | N | N | N | N | | N | 4 | | Abdominal | | | | | | | | | | | | Intraoperative (Abdominal) | | | | | | | | | | | | Intraoperative Neurological | | | | | | | | | | | | Pediatric | | | | | | | | | | | | Small Organ [1] | | | | | | | | | | | | Neonatal Cephalic | | | | | | | | | | | | Adult Cephalic | | | | | | | | | | | | Cardiac [2] | | | | | | | | | | | | Transesophageal (Cardiac) | | | | | | | | | | | | Transesophageal (Non Cardiac) | | | | | | | | | | | | Transrectal | N | N | N | N | N | N | N | | N | 4 | | Transvaginal | N | N | N | N | N | N | N | | N | 4 | | Transurethral | | | | | | | | | | | | Intravascular | | | | | | | | | | | | Peripheral Vascular (including vascular access) | | | | | | | | | | | | Laparoscopic | | | | | | | | | | | | Musculo-skeletal Conventional (including Nerve Blocking) | | | | | | | | | | | | Musculo-skeletal Superficial (including Nerve Blocking) | | | | | | | | | | | | Other (Urological) | N | N | N | N | N | N | N | | N | 4 | The SE3123 probe is to be cleared via this submssion Nenew indication; P=previously cleared by FDA; E= added under Appendix E Additional Comments: - (1) Small Organs includes Breast, Thyroid and Testicles (2) Cardiac is Adult and Pediatric (3) Combined modes are: B + M + PW + CFM + PD ' [4] XVicw Prescription Use Only (Per 21 CFR 801 Part D) Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD) Signature (Division Sign-Off) Division of Radiological Devices Office of In Vitro Diagnostic Devices Office of In Vitro Diagnostic Device Evaluation and Safety 510K K116605